Through the partnership, Pfizer will use Ginkgo’s biotechnology to discover and develop novel RNA molecules. While Ginkgo will receive the upfront payment of up to $331 million, it could also receive revenue from royalties on potential future sales, according to a Sept. 27 Ginkgo news release.
Ginkgo’s platform aims to achieve efficient production, circularization, improved stability and enhanced translation of individual RNA constructs.
“RNA therapeutics are proving to be an important platform to advance the world of scientific innovation, and with progress in synthetic biology we have the potential to create new RNA treatments that may benefit patients worldwide,” Pfizer’s Head of Biomedicine Design Will Somers, PhD, said in the news release. “Access to Ginkgo’s proprietary platform will help enable Pfizer to search for novel and exciting RNA constructs with improved stability and expression that could lead to more effective treatments.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
